					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE	
	Substitute for form 1449A/PTO			COMPLETE IF KNOWN		
	INFORMATION	DIS	CLOSURE	Application Number	10/585,147	
	DIP STATEMENT BY	A D	DI ICANT	Filing Date	June 29, 2006	
	STATEMENT BI	Ar.	FLICANI	First Named Inventor	Christopher Bayly	
	OV 0 2 2006 8		,	Group Art Unit	To be assigned	
屬	(use as many sheets	as n	ecessary)	Examiner Name	To be assigned	
1/3	e share of 1	of	3	Attorney Docket Number	МС099ҮР	

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Documer Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY				
`•									

	FOREIGN PATENT DOCUMENTS									
F	G.,		Foreign Patent Document			Date of Publication of				
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY				
			WO 2004/033445		Merck Frosst Canada & Co.	04/22/2004				
			WO 98/50533		Smithkline Beecham Corporation	11/12/1998				
	WO 98/05336			Smithkline Beecham Corporation	02/12/1998					
			WO 01/70232		Smithkline Beecham Corporation	09/27/2001				
			WO 01/95911		Smithkline Beecham Corporation	12/20/2001				
			WO 00/69855		Medivir UK Limited	11/23/2000				
			WO 02/088106		Medivir AB	11/07/2002				
			WO 02/057248		Incenta Limited	07/25/2002				
			WO 02/057270		Incenta Limited	07/25/2002				
			WO 02/057246		Incenta Limited	07/25/2002				

Examiner Signature /Bernard Dentz/ Date Considered 03/25/2010

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SENDIOR COMMUNICATION OF C

St	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN			
I	NFORMATIO	N DIS	CLOSURE	Application Number	10/585,147		
6	TATEMENT B	37 A D	DI ICANT	Filing Date	June 29, 2006		
3	TALEMENT	Y AP	PLICANI	First Named Inventor	Christopher Bayly		
			,	Group Art Unit	To be assigned		
	(use as many she	ets as n	ecessary)	Examiner Name	To be assigned		
Sheet	2	of	3	Attorney Docket Number	мС099ҮР		

U.S. PATENT DOCUMENTS								
Cite		ent		Date of Publication of Cited Document				
140.	Number	(if known)	of Cited Document	MM-DD-YYYY				
								
•								
	·							
				// // // // // // // // // // // // //				
	Cite No.	Cite	U.S. Patent Document Cite Kind	Cite No. Number Code (if known) Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant of Cited Document				

FOREIGN PATENT DOCUMENTS									
Examiner	C:t-		Foreign Patent Document		V (D)	Date of Publication of			
Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY			
			WO 02/057249		Incenta Limited	07/25/2002			
	<u> </u>								
	<u> </u>	ļ <u> </u>							
		<u> </u>		_ -					
		ļ		_					
لِـــِــا	<u></u>				<u> </u>				

Examiner Signature /Bernard Dentz/ Date Considered 03/25/2010

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.D./

	ubstitute for form 1449B/PTO			COMPLETE IF KNOWN			
1	NFORMATION]	DIS	CLOSURE	Application Number	10/585,147		
6	TATEMENT BY	A TO	DI ICANT	Filing Date	June 29, 2006		
3	IAIEMENI BY	AP	PLICANI	First Named Inventor	Christopher Bayly		
	6.55 5.5 l4-			Group Art Unit	To be assigned		
	(use as many sheets	as n	ecessary)	Examiner Name	To be assigned		
Sheet	3	of	3	Attorney Docket Number	МС099ҮР		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
		Saftig, P et al., PNAS: Proceedings of the National Academy of Sciences, Vol. 95, pp 13453-13458 (1998), "Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice"					
		Thompson, SK et al., PNAS: Proceedings of the National Academy of Sciences, Vol. 94, pp 14249-14254 (1997), "Design of potent and selective human cathepsin K inhibitors that span the active site"					
•							

Examiner Signature /Bernard Dentz/ Date Considered 03/25/2010			
0.5.1.2.1.0 Vol. 2.3/2.0 IV	/Bernard Dentz/	Date Considered	03/25/2010

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.D./